Sensitizing brain metastases to stereotactic... (2022 study) Skip to main content
Clinical Study Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2022

Sensitizing brain metastases to stereotactic radiosurgery using hyperbaric oxygen: A proof-of-principle study.

Hartford AC, Gill GS, Ravi D, Tosteson TD, Li Z, Russo G, et al., Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers gave hyperbaric oxygen to 19 patients with brain metastases just before stereotactic radiosurgery and compared them with 19 matched historical controls to check feasibility, safety and response.

What They Found

In this small non-randomised study of 38 patients, adding hyperbaric oxygen before radiosurgery was feasible and showed no significant difference from controls in radionecrosis-free survival, local recurrence-free survival, distant recurrence-free survival or overall survival. The HBO group had 25 brain metastases and the controls had 27. The average time from the HBO chamber to radiosurgery beam-on was 8.3 minutes, give or take 1.7. Reported side effects were comparable between groups, and no grade III or IV serious adverse events were seen. One-year estimated rates were numerically higher with HBO, for example overall survival 73% versus 56% and local recurrence-free survival 95% versus 78%, but the differences were not statistically significant. Tumor resection was linked to radionecrosis and to overall survival, and higher GPA was linked to overall survival (p less than 0.05 for these).

What This Means for Canadian Patients

For people with brain metastases, this study shows that giving hyperbaric oxygen shortly before radiosurgery could be done in a small group without an evident increase in radiation necrosis or other serious adverse events. It does not show that HBO improves tumor control or survival, because the differences seen were not statistically significant. Anyone considering this should discuss it with their radiation oncology team.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The study was small, used historical controls instead of random assignment, and found no statistically significant differences between groups, so it cannot show whether HBO helps or harms outcomes.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Clinical Study
Category Radiation Injury
Source Pubmed
PubMed ID 36404528
Year Published 2022
Journal Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
MeSH Terms Humans; Radiosurgery; Brain Neoplasms; Cranial Irradiation; Quality of Life; Hyperbaric Oxygenation; Treatment Outcome; Retrospective Studies; Radiation Injuries; Oxygen

Cite This Study

Share

This study relates to Delayed Radiation Injury. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology